Apixaban use is rising for atrial fibrillation and atrial flutter in patients with end-stage renal disease, reflecting a practice shift over a 5-year period.
Observational
Yes
What are the real-world prescribing trends for apixaban in patients with atrial fibrillation and atrial flutter with end-stage renal disease?
Patients with atrial fibrillation (AF) and atrial flutter (AFL) with end-stage renal disease (ESRD) have historically been excluded from pivotal DOAC trials, and earlier guidelines discouraged their use. The 2023 ACC/AHA/ACCP/HRS guideline cautiously endorsed apixaban or warfarin as reasonable options (Class 2b), yet real-world prescribing trends for anticoagulation in this setting remain poorly described.
Abumuhfouz et al. (Wed,) conducted a observational in Atrial fibrillation and atrial flutter with end-stage renal disease. Apixaban was evaluated on Prescribing trends for anticoagulation. Apixaban use is rising for atrial fibrillation and atrial flutter in patients with end-stage renal disease, reflecting a practice shift over a 5-year period.